Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

Company

Phost'in Therapeutics

Phost'in Therapeutics_logo
30
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs targeting a key glycosylation mechanism responsible for suppressing the immune response.

Montpellier, Occitanie, France

Send a message

Anglais

Phost'in Therapeutics

Anglais

Phost’In develops a new class of highly potent anti-cancerous NCEs targeting glycosylation: mechanism of action consists in modifying the cancer cell glycocalyx, which results in inducing an anti-cancer immune response and down modulating cancer invasiveness. 

Using its expertise on phosphorus chemistry, 400 molecules have already been synthetized, with a first Drug Candidate PST3.1a qualified on various indications....

See more

Phost’In develops a new class of highly potent anti-cancerous NCEs targeting glycosylation: mechanism of action consists in modifying the cancer cell glycocalyx, which results in inducing an anti-cancer immune response and down modulating cancer invasiveness. 

Using its expertise on phosphorus chemistry, 400 molecules have already been synthetized, with a first Drug Candidate PST3.1a qualified on various indications. First-in-Human is planned to be launched by the 12 months, with 3 cohorts of patient from different cancers including our first targeted pathology Glioblastoma (GBM).

Qualified in vivo on subcutaneous and orthotopic mice models, PST3.1a has demonstrated strong antitumoral activity associated with a significant median survival. The compound shows an excellent safety profile, and passes through the blood brain barrier. Furthermore, it inhibits invasiveness and metastatic process.

IP portfolio includes 1 proprietary patent (2016 - covering Lead PST3.1a) and an international exclusive license with sublicensing rights on 2 original academic patents covering the PhostineTM family.

Created in 2014, the company was awarded a special prize in the 2014 ILab competition of the French Research Ministry, and raised €1.8m in equity so far.

Within 4 years, the objective is to boost the value of the platform by licensing PST3.1a and generating new IP (new compounds / new indications). 

  • 3

    Followers

  • 3

    Like

Our network

Your request has been sent
Join this network
Your message has been sent

Communities

Les Deeptech
Les Deeptech, c’est la communauté qui rassemble les startups deeptech françaises et les investisseurs désirant développer des relations business avec elles.
287 Members
SATT
SATTs are Societies By Simplified Actions created by several public research centers as part of the "Investments for the Future" Program (french PIA); within the commercialization department.
279 Members
InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2638 Members